ArticleNeurochemical research2005
Neuroprotective effects of ebselen on experimental spinal cord injury in rats.
Article in Neurochemical research, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 69 citations in OpenAlex.
- The role of antioxidants in facial nerve injury.Frontiers in molecular biosciences · 2025Review
- The Effectiveness of Ebselen in Facial Nerve Crush Injury: An Experimental Study.The journal of international advanced otology · 2024Article
- Lithium promotes recovery after spinal cord injury.Neural regeneration research · 2022Article
- Toxicology and pharmacology of synthetic organoselenium compounds: an update.Archives of toxicology · 2021Review
- Novel Selenium-based compounds with therapeutic potential for SOD1-linked amyotrophic lateral sclerosis.EBioMedicine · 2020Article
- Ebselen as template for stabilization of A4V mutant dimer for motor neuron disease therapy.Communications biology · 2020Article
- The role of NOX inhibitors in neurodegenerative diseases.IBRO reports · 2019Review
- Use of ebselen as a neuroprotective agent in rat spinal cord subjected to traumatic injury.Neural regeneration research · 2019Article
- Regulatory effect of neuroglobin in the recovery of spinal cord injury.The journal of spinal cord medicine · 2019Article
- Hypothermic treatment after computer-controlled compression in minipig: A preliminary report on the effect of epidural vs. direct spinal cord cooling.Experimental and therapeutic medicine · 2018Article
- Genistein Loaded Nanofibers Protect Spinal Cord Tissue Following Experimental Injury in Rats.Biomedicines · 2018Article
- Discovery of ebselen as an inhibitor of Cryptosporidium parvum glucose-6-phosphate isomerase (CpGPI) by high-throughput screening of existing drugs.International journal for parasitology. Drugs and drug resistance · 2018Article
- Different dose-dependent effects of ebselen in sciatic nerve ischemia-reperfusion injury in rats.Bosnian journal of basic medical sciences · 2015Article
- Review
- Neuroprotective effects of sildenafil in experimental spinal cord injury in rabbits.Bosnian journal of basic medical sciences · 2015Article
- Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathways.Molecular biology reports · 2014Review
- Article
- Evaluation of the neurotoxic/neuroprotective role of organoselenides using differentiated human neuroblastoma SH-SY5Y cell line challenged with 6-hydroxydopamine.Neurotoxicity research · 2012Article
- Methylmercury-induced alterations in astrocyte functions are attenuated by ebselen.Neurotoxicology · 2011Article
- Catalase and glutathione peroxidase mimics.Biochemical pharmacology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) results in rapid and significant oxidative stress. This study was aimed to investigate the possible beneficial effects of Ebselen in comparison with Methylprednisolone in experimental SCI. Thirty six Wistar albino rats (200-250 g) were divided in to six groups; A (control), B (only laminectomy), C (Trauma; laminectomy + spinal trauma), D (Placebo group; laminectomy + spinal trauma + serum physiologic), E (Methylprednisolone group; laminectomy + spinal trauma + Methylprednisolone treated), F (Ebselen group; laminectomy + spinal trauma + Ebselen treated), containing 6 rats each. Spinal cord injury (SCI) was performed by placement of an aneurysm clip, extradurally at the level of T11-12. After this application, group A, B and C were not treated with any drug. Group D received 1 ml serum physiologic. Group E received 30 mg/kg Methylprednisolone and, Group F received 10 mg/kg Ebselen intraperitoneally (i.p.). Rats were neurologically examined 24 h after trauma and spinal cord tissue samples had been harvested for both biochemical and histopathological evaluation. All rats were paraplegic after SCI except the ones in group A and B. Neurological scores were not different in traumatized rats than that of non-traumatized ones. SCI significantly increased spinal cord tissue malondialdehyde (MDA) and protein carbonyl (PC) levels and also decreased superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (CAT) enzyme activities compared to control. Methylprednisolone and Ebselen treatment decreased tissue MDA and PC levels and prevented inhibition of the enzymes SOD, GSH-Px and CAT in the tissues. However, the best results were obtained with Ebselen. In groups C and D, the neurons of the spinal cord tissue became extensively dark and degenerated with picnotic nuclei. The morphology of neurons in groups E and F were very well protected, but not as good as the control group. The number of neurons in the spinal cord tissues of the groups C and D were significantly less than the groups A, B, E and F. We concluded that the use of Ebselen treatment might have potential benefits in spinal cord tissue damage on clinical grounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.